Three-Pronged attack: new combo therapy aims to wipe out advanced throat cancer
NCT ID NCT06592599
Summary
This study is testing a new three-drug combination (gemcitabine, docetaxel, and toripalimab) given before standard radiation therapy for people with a specific type of advanced throat cancer (EBV-positive nasopharyngeal carcinoma). The goal is to see if this approach is safe, feasible, and more effective at shrinking tumors and achieving complete responses. The trial will enroll about 24 adults who have not had prior treatment for this cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
RECRUITINGPalo Alto, California, 94304, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.